Corcia Philippe, Lunetta Christian, Vourc'h Patrick, Pradat Pierre-François, Blasco Hélène
CRMR SLA, CHU Tours, Tours, France.
UMR1253 iBrain UMR, Université de Tours, INSERM, Tours, France.
Eur J Neurol. 2023 May;30(5):1459-1464. doi: 10.1111/ene.15738. Epub 2023 Feb 23.
Amyotrophic lateral sclerosis (ALS) is among the most common motor neuron diseases in adults. Nevertheless, ALS remains fatal, despite decades of research and clinical trials, which has led to negative conclusions until recently in regard to four specific treatments. It is well known that we can learn from failures, and we consider that the time has come to present positive insight on this disease.
We did a literature search using PubMed and Scopus for articles published in English from 1 January 2016, to 30 June 2022 dealing with "amyotrophic lateral sclerosis", diagnosis, treatment, and biomarkers.
A comprehensive review of the literature on diagnosis, monitoring, and treatment of this condition showed convincing evidence that we are now able to diagnose earlier as well as to better monitor and treat ALS.
Although ALS is often difficult to diagnose and remains incurable, there are many indications that an optimistic view of ALS management in the coming years is now realistic.
肌萎缩侧索硬化症(ALS)是成人中最常见的运动神经元疾病之一。然而,尽管经过数十年的研究和临床试验,ALS仍然是致命的,直到最近,针对四种特定治疗方法的研究都得出了负面结论。众所周知,我们可以从失败中吸取教训,我们认为现在是时候对这种疾病给出积极见解了。
我们使用PubMed和Scopus对2016年1月1日至2022年6月30日期间发表的关于“肌萎缩侧索硬化症”、诊断、治疗和生物标志物的英文文章进行了文献检索。
对该疾病诊断、监测和治疗的文献进行全面综述后发现,有令人信服的证据表明,我们现在能够更早地诊断以及更好地监测和治疗ALS。
尽管ALS通常难以诊断且仍然无法治愈,但有许多迹象表明,对未来几年ALS治疗持乐观态度现在是现实的。